View source for CT Tumor Volume Change for Advanced Disease, Clinically Feasible Profile

[[File:QIBA Initials FIN.JPG|right|frameless|link=https://qibawiki.rsna.org/index.php/File:QIBA_Initials_FIN.JPG]]

==='''<big>[[Media:QIBACTVol TumorVolumeChange 2022Jul21.pdf|Document (PDF)]]</big>'''===
===<u>Publication Details</u>===
Author: QIBA CT Volumetry Biomarker Committee

Version: Stage 3: Clinically Feasible

DOI: 10.1148/QIBA/20220721

Publication date: 2022 July 21

===<u>Executive Summary</u>===
A QIBA Profile is an implementation guide to generate a biomarker with an effective level of performance, mostly by reducing variability and bias in the measurement.

The expected performance is expressed as Claims (Section 1.2). To achieve those claims, Actors (Scanners, Technologists, Physicists, Radiologists, Reconstruction Software, and Image Analysis Tools) must meet the Checklist Requirements (Section 3) covering Periodic QA, Subject Handling, Image Data Acquisition, Image Data Reconstruction, Image QA, and Image Analysis.

This Profile is at the Clinically Feasible stage (qibawiki.rsna.org/index.php/QIBA_Profile_Stages) so,
*The requirements have been performed and found to be practical by multiple sites
*The claim is a hypothesis based on committee assessment of literature and QIBA groundwork

QIBA Profiles for other CT, MRI, PET, and Ultrasound biomarkers can be found at qibawiki.rsna.org

===<u>Clinical Context</u>===
CT Tumor Volume Change is used as a biomarker of disease risk, characterization, progression, and response to treatment.

This involves measuring tumor volumes and assessing longitudinal changes within subjects, based on image processing of CT scans acquired at different timepoints. See Appendix B for a discussion of usage of this biomarker in practice.